Spike Lo

VP of Business Development
AP Biosciences, Inc.

​

As Vice President of Business Development at AP Biosciences, I am honored to represent a team dedicated to advancing innovative therapies through our proprietary bispecific antibody platform. With over 15 years of experiences across the pharmaceutical and biotech sectors, I bring a strategic lens to our company’s global partnering efforts and clinical asset development. AP Biosciences is the first biotech in Taiwan to develop clinical-stage bispecific antibodies, with a pipeline targeting critical unmet needs in solid tumor immunotherapy.
In my current role, I lead global business development strategy and oversee external partnerships across our lead clinical programs- AP505, AP203, AP402, and AP601. These assets reflect our company’s commitment to the global healthcare community for the first-in-class mechanisms and translational impact.
Working with leading global pharmaceutical companies including Janssen and Eli Lilly, as well as premier clinical research organizations such as ICON Clinical Research and IQVIA, I gained comprehensive insights into the complexities of clinical development and strategic collaboration. This experience enables me to bridge scientific innovation with business strategy, driving meaningful alliances that support AP Biosciences' international growth.
What defines our company and inspires my work, is a belief that breakthrough science must be paired with smart execution from the global perspective. As we continue to expand our reach through partnerings and collaborations, I remain committed to bringing transformative therapies to patients and to showcasing Taiwan’s growing impact in the global biotech community.​

 

Speech title & Synopsis

Company Profile

AP Biosciences is a clinical-stage biopharmaceutical company dedicated to advancing next-generation cancer immunotherapies through innovative bispecific antibodies. Since its founding in 2013, AP Biosciences has focused on the discovery and development of antibody-based therapeutics, with deep expertise in CD137-based T-cell engagers and immune pathway modulation. Leveraging proprietary platforms—the OmniMab Naïve Antibody Phage Display Library and the T-cube Bispecific Antibody Platform—we design fully human bispecific antibodies that target solid tumors and enhance immune response in the tumor microenvironment.
 
Our growing pipeline includes five bispecific antibody programs, four of which have entered clinical development. AP203 (PD-L1 × CD137), targeting patients relapsed from PD-1/PD-L1 therapies, entered Phase 1 trials in Taiwan in 2023 and is preparing for a regional Phase 2 study in 2026. AP402 (p95HER2 × CD137), developed for HER2-refractory cancers, began first-in-human trials in Australia in 2024. AP601 (CD73 × CD137) is on track for IND submission in Australia by Q3 2025. These programs aim to address high unmet needs in solid tumors by combining checkpoint modulation with targeted and conditional T-cell activation.
 
AP Biosciences has also demonstrated strong translational execution and partnering capabilities. We have completed two successful out-licensing deals: IBI302 (VEGF × C4/C5) with Innovent Biologics and B1962/AP505 (PD-L1 × VEGF) with Tasly Pharmaceuticals, validating our scientific foundation and collaborative approach.
 
In 2023, AP Biosciences was listed on the Emerging Stock Board of the Taiwan Stock Exchange (TWSE: 6945) and secured $96 million in last 4 financing rounds to support continued clinical advancement. Our ability to rapidly translate discovery into clinical-stage assets underscores our position as a nimble and globally connected biotech innovator.
 
At AP Biosciences, we believe bispecific antibodies represent a transformative modality for cancer treatment. Through focused development, proprietary innovation, and strategic partnerships, we are committed to delivering meaningful therapies to patients worldwide.